Back to search
FDAFDA · Food and drugs·Recall number D-0616-2018

Fabior (tazarotene) Foam, 0.1%, 100 grams can, Rx only, Distributed by: Mayne Pharma, Greenville, NC 27834; NDC 51862-295-10.

Published April 11, 2018 · Recall initiated: March 21, 2018

Summary

FDA records drug Class III recall D-0616-2018, published April 11, 2018 and initiated March 21, 2018. Recalling firm: Mayne Pharma Inc; Status: Terminated; Reported quantity: 3312 cans; Lot: Lot: MBEB, Exp. 01/31/2019. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Superpotent Drug: High out of specification results for tazarotene assay at the 9-month stability time point.

What to do

Voluntary: Firm initiated · Letter

Get an email if FABIOR has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
FABIOR
Manufacturer
Mayne Pharma Inc
Distributor
Nationwide in the USA
Lot
Lot: MBEB, Exp. 01/31/2019
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Fabior (tazarotene) Foam, 0.1%, 100 grams can, Rx only, Distributed by: Mayne Pharma, Greenville, NC 27834; NDC 51862-295-10. recalled?

Yes. FDA published recall D-0616-2018 on April 11, 2018. Reported hazard: Superpotent Drug: High out of specification results for tazarotene assay at the 9-month stability time point.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: FABIOR.